A retrospective study compared older patients with mRCC with younger ones to determine if age and potential comorbidities is a barrier to clinical trial participation.
At RCC diagnosis, patients with an neutrophil-lymphocyte ratio (NLR) above 3.0 and concomitant hyponatremia had a significant 2.8-fold increased risk of death compared with those who had an NLR of 3.0 or lower and normal sodium levels, a Danish study found.
Among patients undergoing surgery for 10 cm or larger renal cell carcinoma tumors, right-sided tumors are independently associated with improved cancer-specific survival compared with left-sided tumors, a study found.
Updated European Association of Urology guidelines recommend pembrolizumab plus axitinib or ipilimumab plus nivolumab for the first-line treatment of metastatic clear-cell renal cell carcinoma.
In a post hoc analysis of a phase 1 trial, nivolumab treatment was associated with long-term survival in a subset of patients with advanced renal cell carcinoma, melanoma, and non-small cell lung cancer.
Uniform use of computed tomography for hematuria workups marginally increases detection of urinary tract cancers while raising the risk for secondary cancers from imaging-associated radiation, researchers concluded.
Among patients with pT1b renal cell carcinoma, cryoablation is associated with a 2.5-fold higher 5-year cancer-specific mortality rate compared with partial nephrectomy, a study found.
Within the first 2 lines of treatment, patients with metastatic renal cell carcinoma who remain on a drug for at least 3 months have longer overall survival than those who do not, a study found.
Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab) have been made available by Amgen and Allergan.
In a meta-analysis, partial and radical nephrectomy were associated with similar long-term overall survival, but cancer-specific survival was better with radical nephrectomy.
Outside of clinical trials, targeted therapies for advanced renal cell carcinoma in Medicare patients are associated with modest survival advantages over non-targeted therapies.
Nivolumab plus ipilimumab, both checkpoint inhibitors, exhibit promising anti-tumor activity in patients with advanced renal cell carcinoma with brain metastases, researchers report.
